• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-肾上腺素能受体阻滞剂与中枢神经系统相关主观症状:美托洛尔缓释片/佐剂、阿替洛尔和普萘洛尔长效制剂在健康受试者中的随机、双盲、安慰剂对照比较

Beta-adrenoceptor blockade and CNS-related subjective symptoms: a randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healthy subjects.

作者信息

Dimenäs E, Kerr D, Macdonald I

机构信息

Research Laboratories, AB Hässle, Mölndal, Sweden.

出版信息

J Clin Pharmacol. 1990 Feb;30(S2):S103-7. doi: 10.1002/j.1552-4604.1990.tb03506.x.

DOI:10.1002/j.1552-4604.1990.tb03506.x
PMID:1968912
Abstract

The effect of once daily treatment with atenolol (100 mg), metoprolol CR/ZOK (100 mg) and propranolol LA (160 mg) for one week on CNS-related subjective symptoms was compared with that of placebo using a randomised, double-blind cross-over design in 12 healthy volunteers. The symptoms were recorded using a previously documented self-administered questionnaire (MSE-profile), which included three dimensions: Contentment, Vitality and Sleep. Compared to placebo, all three beta-adrenoceptor antagonists reduced the exercise heart rate at 24 hours but a somewhat more pronounced effect was found with propranolol LA. No significant difference in any of the dimensions was detected between placebo and either metoprolol CR/ZOK or atenolol tablets. Following propranolol LA treatment a deterioration in the dimensions Vitality and Sleep was observed compared with both placebo and the beta 1-selective drugs. Difference in lipophilicity between the beta 1-selective agents metoprolol and atenolol has little bearing on the occurrence of the CNS-related symptoms, in comparison to the marked effects of the lipophilic and nonselective compound propranolol.

摘要

在12名健康志愿者中,采用随机、双盲交叉设计,比较了阿替洛尔(100毫克)、美托洛尔控释片/琥珀酸盐(100毫克)和普萘洛尔长效制剂(160毫克)每日一次治疗一周对中枢神经系统相关主观症状的影响与安慰剂的效果。使用先前记录的自我管理问卷(MSE-profile)记录症状,该问卷包括三个维度:满意度、活力和睡眠。与安慰剂相比,所有三种β-肾上腺素能受体拮抗剂均降低了24小时运动心率,但普萘洛尔长效制剂的效果更为明显。在安慰剂与美托洛尔控释片/琥珀酸盐或阿替洛尔片之间,未检测到任何维度上的显著差异。与安慰剂和β1选择性药物相比,普萘洛尔长效制剂治疗后,活力和睡眠维度出现恶化。与亲脂性和非选择性化合物普萘洛尔的显著影响相比,β1选择性药物美托洛尔和阿替洛尔之间的亲脂性差异对中枢神经系统相关症状的发生影响不大。

相似文献

1
Beta-adrenoceptor blockade and CNS-related subjective symptoms: a randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healthy subjects.β-肾上腺素能受体阻滞剂与中枢神经系统相关主观症状:美托洛尔缓释片/佐剂、阿替洛尔和普萘洛尔长效制剂在健康受试者中的随机、双盲、安慰剂对照比较
J Clin Pharmacol. 1990 Feb;30(S2):S103-7. doi: 10.1002/j.1552-4604.1990.tb03506.x.
2
Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol.
J Clin Pharmacol. 1990 Feb;30(S2):S82-90. doi: 10.1002/j.1552-4604.1990.tb03502.x.
3
Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol.控释(CR/ZOK)美托洛尔在健康东方受试者中的药代动力学和药效学特性:与美托洛尔和阿替洛尔常规制剂的比较。
J Clin Pharmacol. 1990 Feb;30(S2):S39-45. doi: 10.1002/j.1552-4604.1990.tb03494.x.
4
Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects.β-肾上腺素能受体阻滞剂与低血糖症。美托洛尔控释片、阿替洛尔和普萘洛尔长效制剂在正常受试者中的随机、双盲、安慰剂对照比较。
Br J Clin Pharmacol. 1990 Jun;29(6):685-93. doi: 10.1111/j.1365-2125.1990.tb03689.x.
5
CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.β1-肾上腺素能受体拮抗剂(阿替洛尔、美托洛尔)治疗期间的中枢神经系统相关主观症状:两项双盲安慰剂对照研究。
Br J Clin Pharmacol. 1989 Nov;28(5):527-34. doi: 10.1111/j.1365-2125.1989.tb03538.x.
6
Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being.100毫克控释美托洛尔和100毫克阿替洛尔对血压、中枢神经系统相关症状及总体健康状况的影响。
J Clin Pharmacol. 1994 Jul;34(7):742-7. doi: 10.1002/j.1552-4604.1994.tb02034.x.
7
Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years.
J Clin Pharmacol. 1990 Feb;30(S2):S108-16. doi: 10.1002/j.1552-4604.1990.tb03507.x.
8
Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses.美托洛尔控释/缓释片每日一次与普通片剂每日一次及分次给药的药代动力学和药效学比较。
J Clin Pharmacol. 1990 Feb;30(S2):S17-27. doi: 10.1002/j.1552-4604.1990.tb03491.x.
9
Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.
Eur J Clin Pharmacol. 1990;38(6):571-8. doi: 10.1007/BF00278584.
10
A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.每日一次服用美托洛尔控释片与阿替洛尔治疗中国轻至中度高血压患者的双盲比较。
Cardiovasc Drugs Ther. 1995 Jun;9(3):401-6. doi: 10.1007/BF00879028.

引用本文的文献

1
Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.美托洛尔:对其用于高血压、心肌梗死后及扩张型心肌病的药物经济学与生活质量评估
Pharmacoeconomics. 1994 Oct;6(4):370-400. doi: 10.2165/00019053-199406040-00004.
2
Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics.抗高血压治疗的成本效益:美托洛尔与噻嗪类利尿剂的比较。
Pharmacoeconomics. 1993 Jan;3(1):36-44. doi: 10.2165/00019053-199303010-00005.
3
Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.
腰椎脑脊液中的受体占有率作为阿替洛尔、美托洛尔和普萘洛尔在中枢神经系统中拮抗活性的一种衡量指标。
Br J Clin Pharmacol. 1993 May;35(5):507-15. doi: 10.1111/j.1365-2125.1993.tb04177.x.
4
Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.控释美托洛尔制剂。其药效学和药代动力学特性以及在高血压和缺血性心脏病治疗中的应用综述。
Drugs. 1992 Mar;43(3):382-414. doi: 10.2165/00003495-199243030-00006.